Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENTE phase 2 rechallenge of encorafenib + binimetinib + cetuximab in BRAF V600E-mutant metastatic colorectal cancer
jRCTs031210511Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib, binimetinib and cetuximab in colorectal cancer (CRC), sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate. Started Jan 2022; status: completed.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031210511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210511.